Tysabri has been in the news again this week. Last Friday the European Medicines Agency (EMEA) announced that they would review the benefits and risks for Tysabri.
The Committee started a review of the benefits and risks of Tysabri, in view of reports of 23 cases of progressive multifocal leukoencephalopathy (PML) worldwide since Tysabri has been on the market. This review is initiated to discuss any additional measures necessary to ensure the safe use of Tysabri and how to balance the...
Of the available disease-modifying treatments for multiple sclerosis, Tysabri (natalizumab) has arguably been the most controversial to... Read more »
Held in Montreal last week was the largest single gathering of MS clinicians and researchers at the World Congress on Treatment and... Read more »
No, this is not the beginning of a Scrabble® game. PML stands for Progressive Multifocal Leukoencephalopathy. Is that even more confusing?... Read more »
(Dow Jones) - “Tysabri...caused 22 suspected cases of a rare brain infection through early October...a level deemed unalarming by... Read more »
While PML (progressive multifocal leukoencephalopathy) sounds scary, advances are being made in its diagnosis and treatment. The first... Read more »
Featuring Content From:
By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2013 Remedy Health Media, LLC. All Rights Reserved.
Test Your MS Knowledge 
10 Symptoms That Could Be MS 
Unusual Multiple Sclerosis Symptoms 
10 Foods That Fight Inflammation 
